OSENI pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem	⤷ Get Started Free	B1261503	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 27, 2025

Introduction

Oseni, marketed as a treatment for type 2 diabetes mellitus, contains the active pharmaceutical ingredient (API) alogliptin. As a dipeptidyl peptidase-4 (DPP-4) inhibitor, alogliptin enhances incretin levels, leading to improved glycemic control. With the rising global incidence of diabetes, the demand for alogliptin persists, necessitating a reliable and high-quality supply chain for bulk API. This article explores the primary sources for alogliptin APIs, covering manufacturing regions, key producers, and considerations for procurement.

1. Overview of Alogliptin API Manufacturing

Alogliptin is a synthetic compound with specific molecular and stereochemical features requiring precise manufacturing controls. Major pharmaceutical companies and API manufacturers globally produce it under strict Good Manufacturing Practices (GMP) standards. The key regions for API production include China, India, Europe, and the United States. Each region hosts manufacturers with varying capabilities concerning quality standards, certification, and volume capacity.

2. Leading API Suppliers for Alogliptin

a. China-Based Manufacturers

China sustains a significant share of the global API market, including alogliptin. Chinese API factories benefit from extensive infrastructure, cost efficiencies, and scale advantages, making them prominent suppliers.

Major Players and Capabilities:
Several Chinese companies specializing in DPP-4 inhibitors and other complex APIs supply alogliptin bulk powders. Notable firms include Zhejiang Hisun Pharmaceutical Co., Ltd., and Shanghai Sinepharm Co., Ltd., which have achieved GMP certification and export licenses. These manufacturers often provide competitive pricing but require rigorous due diligence to confirm phase-appropriate GMP compliance and regulatory adherence for export markets.
Certifications & Quality Assurance:
Many Chinese APIs are approved or certified under ISO, GMP, and international standards, though verification of authenticity and batch consistency remains vital. Engaging with suppliers holding certifications from the United States FDA, EMA, or WHO prequalification tables enhances reliability.

b. Indian API Producers

India boasts an established API manufacturing sector with a broad portfolio of generic and specialty APIs, including alogliptin.

Key Manufacturers:
Companies like Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, and Biocon have expanded into the complex API space, offering alogliptin with a focus on quality and regulatory compliance.
Advantages:
Indian manufacturers often provide high-quality APIs at competitive prices with strong compliance records. Many hold multiple certifications, including ISO, USFDA, and EMA approvals, facilitating easier integration into global supply chains.
Supply Chain & Regulatory Considerations:
Indian API makers are subject to stringent inspections and quality audits, especially for export to regulated markets, enhancing trust in their products.

c. European and US API Suppliers

While fewer in number, European and American API producers tend to focus on high-end, quality-assured products for regulated markets.

European Manufacturers:
Companies such as Novartis (which originally developed alogliptin) often outsource API manufacturing to GMP-certified European facilities. These sources prioritize purity, batch-to-batch consistency, and regulatory compliance.
American Suppliers:
USA-based API manufacturers like Cambrex and Pfizer specialize in high-quality APIs and often serve as contract manufacturers, providing APIs that meet rigorous USFDA standards for safety and efficacy.
Market Relevance:
Although less common as direct sources, these suppliers are preferred for supply chain reliability in highly regulated markets, with higher price points offset by stringent quality standards.

3. Contract Manufacturing Organizations (CMOs) and API Brokers

In addition to direct suppliers, many global pharmaceutical companies utilize CMOs and API brokers. These entities can aggregate supplies from multiple sources, ensuring compliance and quality control.

Role in API Sourcing:
CMOs like ACG Worldwide, Siegfried, and Lonza offer custom synthesis for APIs like alogliptin, facilitating large-scale production and supply chain management.
Advantages:
They provide flexibility, quality assurance, and regulatory support, especially for batch verification, stability testing, and documentation.

4. Considerations for Sourcing Alogliptin API

Procurement of alogliptin API requires comprehensive due diligence. Key factors include:

Regulatory Certification: Ensure the supplier holds valid GMP certifications recognized by relevant authorities (e.g., USFDA, EMA, WHO).
Quality Control: Verify purity levels (typically ≥99%), batch consistency, and stability data.
Traceability and Documentation: Insist on CMDRs (Certificates of Drug Master Record) and full batch documentation to ensure traceability.
Pricing and Lead Times: Balance cost considerations with quality, delivery times, and supplier reliability.
Regional Regulations: Comply with local import-export guidelines and regional pharmacovigilance requirements.

5. Future Trends in API Sourcing

As demand for alogliptin and other DPP-4 inhibitors grows, new manufacturing hubs may emerge, with increased focus on Quality by Design (QbD) principles, continuous manufacturing, and sustainable practices. Moreover, geopolitical factors and trade tariffs can influence supply chain dynamics, prompting diversification across regions.

Key Takeaways

The primary global sources for alogliptin API are manufacturers in China, India, Europe, and the United States, each with distinct advantages related to cost, quality, and regulatory compliance.
China and India dominate the supply, offering competitive pricing and reliable GMP-certified products, though buyers should conduct thorough validation.
European and US-based API suppliers focus on premium quality for regulated markets, suitable for high-standard pharmaceutical manufacturing.
Sourcing decisions must prioritize certifiable compliance, batch consistency, documentation, and supplier reputation to mitigate risks.
Contract manufacturing organizations facilitate scalable, compliant production, often serving as intermediaries to ensuring comprehensive quality control.

FAQs

1. What are the main quality considerations when sourcing alogliptin API?
Ensure suppliers possess GMP certifications recognized internationally, verify API purity (typically ≥99%), review batch records, and confirm stability testing data to guarantee product consistency and safety.

2. Is it advisable to source alogliptin API from Chinese manufacturers?
Yes, many Chinese manufacturers are GMP-certified and produce high-quality APIs at competitive prices. However, due diligence, including audits and certification verification, is essential due to variability in certification standards.

3. How does Indian API manufacturing compare for alogliptin?
Indian producers generally offer a good balance of quality, cost efficiency, and regulatory compliance, with many adhering to international standards like USFDA and EMA, making them reputable sources.

4. Are European and US API suppliers more reliable?
They typically provide higher assurance regarding purity and regulatory compliance but at higher costs. They are preferred for highly regulated markets requiring strict quality assurances.

5. How can a pharmaceutical company ensure the authenticity of an alogliptin API supplier?
Conduct thorough audits, request GMP certificates, review production capacity, obtain references from other clients, and verify regulatory approvals to validate supplier credibility.

References

[1] Pharmaceutical Technology. "A Guide to API Manufacturing." 2021.
[2] World Health Organization. "WHO Prequalification Program: Active Pharmaceutical Ingredients." 2022.
[3] U.S. Food & Drug Administration. "Guidance for Industry: Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients." 2020.
[4] Chinese Pharmacopoeia. "Guidelines for API certification." 2021.
[5] Indian Pharmacopoeia. "Standards for Active Pharmaceutical Ingredients." 2022.

Bulk Pharmaceutical API Sources for OSENI